Please login to the form below
EUSA Pharma appoints Rolf Hoffmann to its board
He most recently worked at Amgen for over a decade
Oncology-focused pharmaceutical group EUSA Pharma has added to its board of directors in the form of Rolf Hoffman.
Hoffman, who is currently chairman of Biotest and sits on the board of directors of Genmab, brings over 30 years’ pharmaceutical experience to his new position having served in a number of senior roles in the industry.
He most recently spent 12 years with Amgen as its senior vice president of commercial operations, US and prior to that, he worked for SVP.
Hoffman said: “I have watched EUSA Pharma’s remarkable progress in the three years since it was founded, and am delighted to now help the company achieve its ambitious plans.”
His new role will see him play a role in guiding EUSA’s commercial strategy for its cancer treatments.
Bryan Morton, executive chairman at EUSA Pharma, said: “Rolf’s strategic insight and guidance, based on significant commercial experience in the oncology field will prove invaluable as EUSA launches Qarziba and Fotivda in Europe.”
Subscribe to our email news alerts
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Amgen reports positive results for Otezla in psoriatic arthritis
- Pfizer reports positive results for elranatamab in multiple myeloma
- Amgen’s Lumakras shows promise in phase 3 lung cancer study
- Adaptive innovation
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- Navigating patients step by step on their clinical trial journey
- Innovative Trials responds to national recommendations to tackle UK clinical trial decline
No results were found
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....
Latest intelligence
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
- Tuberculosis – why it remains a major global public health challenge
- Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
